青蒿琥酯；青蒿脂

Artesunate

	产品编号	CFN90313
	CAS编号	88495-63-0
	分子式 = 分子量	C₁₉H₂₈O₈ = 384.42
	产品纯度	>=98%
	物理属性	Powder
	化合物类型	Sesquiterpenoids
	植物来源	The herbs of Artemisia annua L.
ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用

提供自定义包装

产品名称	产品编号	CAS编号	包装	QQ客服
青蒿琥酯；青蒿脂	CFN90313	88495-63-0	10mg	QQ客服：2056216494
青蒿琥酯；青蒿脂	CFN90313	88495-63-0	20mg	QQ客服：2056216494
青蒿琥酯；青蒿脂	CFN90313	88495-63-0	50mg	QQ客服：2056216494
青蒿琥酯；青蒿脂	CFN90313	88495-63-0	100mg	QQ客服：2056216494

存储与注意事项

1. 在您收到产品后请检查产品。如无问题，请将产品存入冰霜并且样品瓶保持密封，产品可以存放长达24个月（2-8摄氏度）。

2. 只要有可能，产品溶解后，您应该在同一天应用于您的实验。但是，如果您需要提前做预实验，或者需要全部溶解，我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。通常，这些可用于长达两周。使用前，打开样品瓶前，我们建议您将产品平衡至室温至少1小时。

3. 需要更多关于溶解度，使用和处理的建议？请发送电子邮件至：service@chemfaces.com

订购流程

1. 在线订购

请联系我们QQ客服

2. 电话订购

请拨打电话：
027-84237683 或 027-84237783

3. 邮件或传真订购

发送电子邮件到: manager@chemfaces.com 或
发送传真到：027-84254680

提供订购信息

为了方便客户的订购，请需要订购ChemFaces产品的客户，在下单的时候请提供下列信息，以供我们快速为您建立发货信息。

1. 产品编号（CAS No.或产品名称）

2. 发货地址

3. 联系方法 (联系人，电话）

4. 开票抬头 (如果需要发票的客户）

5. 发票地址（发货地址与发票地址不同）

发货时间

1. 付款方式为100%预付款客户，我们将在确认收到货款后当天或1-3个工作日发货。

2. 付款方式为月结的客户，我们承诺在收到订单后当天或1-3个工作日内发货。

3. 如果客户所需要的产品，需要重新生产，我们有权告知客户，交货时间需要延期。

Description:

Artesunate is a part of the artemisinin group of agents with an IC50 of < 5 μM for small cell lung carcinoma cell line H69. It is a potential inhibitor of STAT-3 and exhibits selective cytotoxicity of cancer cells over normal cells in vitro; A potent inhibitor of EXP1.Artesunate has anti-inflammatory activity, can prevent neuroinflammation in BV2 microglia by interfering with NF-κB and p38 MAPK signalling.

Targets:

In vitro:

Curr Top Med Chem . 2016;16(22):2453-63.

Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma[Pubmed: 26873192]

Abstract Background: Aberrant signal transducer and activator of transcription 3 (STAT-3) molecular signaling elicit hepatocellular carcinoma (HCC) in humans. Therefore, targeting STAT-3 is considered as an attractive option towards suppression of HCC in humans. Objective: Our objective is to identify a potential small molecule inhibitor that can specifically target STAT-3 and suppress HCC. Methods: In this study, we analyze a group of sesquiterpene lactone (STL) candidates that has been recently reported in preclinical trials against cancer by a unified computational and experimental approach. Results: Our virtual analysis of the STL candidates revealed Artesunate (ATS) as the best potential inhibitor of STAT-3 with comparable potency to specific inhibitor S3I-201. We also observed that ATS inhibited IL-6 driven STAT-3-DNA binding activity with comparable potency to S3I-201 in a cell free system. Furthermore ATS was observed to interfere with STAT-3 dimerization and suppression of both constitutive and IL-6 inducible STAT-3 in vitro. Nevertheless, we also observed that ATS modulated STAT-3 dependent targets (procaspase-3, Bcl-xl and survivin) favoring occurrence of apoptosis in vitro. Overall, the putative inhibition of STAT-3 by ATS suggested its capacity to interfere with STAT-3 dimerization by binding to the SH2 domain of STAT-3 monomer. It resulted in suppression of STAT-3 and also favored promotion of in vitro cells towards apoptosis. Consequently, ATS also exhibited selective cytotoxicity of cancer cells over normal cells in vitro. Conclusion: All the above observations substantiated by unified computational and in vitro experimental approaches suggested its potential role as a therapeutic anti-cancer agent against HCC.

In vivo:

Mutat Res Genet Toxicol Environ Mutagen. 2015 Jan 1;777:1-6.

The antimalarial agent artesunate causes sperm DNA damage and hepatic antioxidant defense in mice.[Pubmed: 25726169]

Artesunate is an artemisinin derivative effective against multidrug resistant malaria.
METHODS AND RESULTS:
We analyzed the effects of artesunate 40 mg/kg b.w. as a single dose (ART1) or 13.3mg/kg b.w. for 3 days at 24h intervals (ART2) on mice spermatozoa at morphological and molecular level, and hepatic antioxidant status following 24h and 35 days following exposures in vivo. Artesunate significantly reduced epididymal sperm count and increased the frequency of sperms with abnormal head morphology following 24h of exposure. Comet assay analysis revealed significant increase in DNA strand breaks in spermatozoa evidenced by about 3-fold increase in comet tail DNA and up to 10-fold increase in Olive tail moment following 35 days of artesunate treatment. The damage index was significantly higher in the treated groups (40.27 ± 6.62 and 37.07 ± 5.35 for ART1 and ART2 respectively) as compared to the control group (16.13 ± 3.21) indicating the genotoxic effect of artesunate. The significant reduction in GSH, SOD and increase in lipid peroxidation indicate involvement of oxidative mechanisms in artesunate induced toxicity in mice.
CONCLUSIONS:
The present study suggests that artesunate has the potential to breach the testis-blood barrier and cause toxicity to male germ cells which may have implications in male reproductive toxicity.

Br J Clin Pharmacol. 2015 Apr 15.

Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation.[Pubmed: 25877779]

To compare the pharmacokinetic properties of Artesunate and dihydroartemisinin in the same women: i) pregnant with acute uncomplicated malaria on day 1 and 2, ii) pregnant with convalescent malaria on day 7 and iii) in a healthy state 3 months post-partum on day 1, 2 and 7.
METHODS AND RESULTS:
Nonlinear mixed-effects modelling was used to compare plasma concentration-time profiles of Artesunate and dihydroartemisinin over 7 days of treatment following oral and intravenous Artesunate administration to pregnant women with uncomplicated Plasmodium falciparum malaria during their second or third trimesters of pregnancy. The same women were restudied three months after delivery when fully recovered. Non-compartmental results of the same study have been published previously.Twenty pregnant patients on the Thailand-Myanmar border were studied and 15 volunteered to be restudied three months post-partum. Malaria and pregnancy had no effect on the pharmacokinetic properties of Artesunate or dihydroartemisinin after intravenous Artesunate administration. However, malaria and pregnancy had opposite effects on the absorption of orally administered Artesunate. Malaria increased the absolute oral bioavailability of Artesunate by 87%, presumably by inhibiting first-pass effect, whereas pregnancy decreased oral bioavailability by 23%.
CONCLUSIONS:
The population pharmacokinetic analysis demonstrated opposite effects of malaria and pregnancy on the bioavailability of orally administered Artesunate. Lower drug exposures during the second and third trimesters of pregnancy may contribute to lower cure rates and thus the development of drug resistance. Dose optimisation studies are required for Artesunate containing ACTs in later pregnancy.

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.6013 mL	13.0066 mL	26.0132 mL	52.0264 mL	65.033 mL
5 mM	0.5203 mL	2.6013 mL	5.2026 mL	10.4053 mL	13.0066 mL
10 mM	0.2601 mL	1.3007 mL	2.6013 mL	5.2026 mL	6.5033 mL
50 mM	0.052 mL	0.2601 mL	0.5203 mL	1.0405 mL	1.3007 mL
100 mM	0.026 mL	0.1301 mL	0.2601 mL	0.5203 mL	0.6503 mL

产品名称	产品编号	CAS编号	分子式 = 分子量	位单	联系QQ
脱氧青蒿素; Deoxyartemisinin	CFN97212	72826-63-2	C₁₅H₂₂O₄ = 266.3	5mg	QQ客服：2159513211
双氢青蒿素; Dihydroartemisinin	CFN99507	71939-50-9	C₁₅H₂₄O₅ = 284.35	20mg	QQ客服：3257982914
蒿甲醚; Artemether	CFN99184	71963-77-4	C₁₆H₂₆O₅ = 298.38	20mg	QQ客服：1457312923
青蒿素; Artemisinin	CFN99011	63968-64-9	C₁₅H₂₂O₅ = 282.3	20mg	QQ客服：1457312923
α-双氢青蒿素; alpha-Dihydroartemisinin	CFN90485	81496-81-3	C₁₅H₂₄O₅ = 284.34	20mg	QQ客服：3257982914
青蒿琥酯；青蒿脂; Artesunate	CFN90313	88495-63-0	C₁₉H₂₈O₈ = 384.42	20mg	QQ客服：1457312923

青蒿琥酯；青蒿脂

Artesunate

信息支持

联系方式

青蒿琥酯； 青蒿脂

Artesunate

信息支持

联系方式

青蒿琥酯；青蒿脂